[Treatment of Paget's disease of bone with ethane-1 hydroxy-1, 1 diphosphonate at low dosage (author's transl)]. 1980

C Alexandre, and M C Chapuy, and C Bressot, and E Vignon, and M Arlot, and L Mathieu, and C Edouard, and C C Johnston, and P J Meunier

Fifty-one patients with Paget's disease were treated during 6 months with ethane-01 hydroxy-1, 1 diphosphonate (EHDP, etidronate) in doses of 5 mg/kg/day. The drug was most effective in relieving pain, at the same time diminishing the uptake of pagetic lesions on quantitative bone scans and lowering by almost 70% the abnormally high serum alkaline phosphatase levels and 24-hour hydroxyproline urinary levels. Histologically, the resorption surfaces and the number of osteoclasts per mm2 of bone tissue were significantly reduced. On follow-up, the improvement persisted for at least one year after treatment was discontinued. EHDP was well tolerated clinically and biologically, and on histological sections no accumulation of osteoid tissue due to impaired mineralization was seen. EHDP at the 5 mg/kg/day dose appears to be effective in the treatment of Paget's disease.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010001 Osteitis Deformans A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry. Paget's Disease of Bone,Osseous Paget's Disease,Paget Disease of Bone,Paget Disease, Bone,Pagets Disease, Bone
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D010758 Phosphorus A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions. Black Phosphorus,Phosphorus-31,Red Phosphorus,White Phosphorus,Yellow Phosphorus,Phosphorus 31,Phosphorus, Black,Phosphorus, Red,Phosphorus, White,Phosphorus, Yellow
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006909 Hydroxyproline A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation. Oxyproline,4-Hydroxyproline,cis-4-Hydroxyproline,4 Hydroxyproline,cis 4 Hydroxyproline

Related Publications

C Alexandre, and M C Chapuy, and C Bressot, and E Vignon, and M Arlot, and L Mathieu, and C Edouard, and C C Johnston, and P J Meunier
February 1982, Revue du rhumatisme et des maladies osteo-articulaires,
C Alexandre, and M C Chapuy, and C Bressot, and E Vignon, and M Arlot, and L Mathieu, and C Edouard, and C C Johnston, and P J Meunier
March 1975, The Journal of endocrinology,
C Alexandre, and M C Chapuy, and C Bressot, and E Vignon, and M Arlot, and L Mathieu, and C Edouard, and C C Johnston, and P J Meunier
June 1982, La Nouvelle presse medicale,
C Alexandre, and M C Chapuy, and C Bressot, and E Vignon, and M Arlot, and L Mathieu, and C Edouard, and C C Johnston, and P J Meunier
January 1974, The Netherlands journal of medicine,
C Alexandre, and M C Chapuy, and C Bressot, and E Vignon, and M Arlot, and L Mathieu, and C Edouard, and C C Johnston, and P J Meunier
June 1978, Kaku igaku. The Japanese journal of nuclear medicine,
C Alexandre, and M C Chapuy, and C Bressot, and E Vignon, and M Arlot, and L Mathieu, and C Edouard, and C C Johnston, and P J Meunier
October 1975, Lancet (London, England),
C Alexandre, and M C Chapuy, and C Bressot, and E Vignon, and M Arlot, and L Mathieu, and C Edouard, and C C Johnston, and P J Meunier
October 1985, Revista clinica espanola,
C Alexandre, and M C Chapuy, and C Bressot, and E Vignon, and M Arlot, and L Mathieu, and C Edouard, and C C Johnston, and P J Meunier
April 1984, Clinical orthopaedics and related research,
C Alexandre, and M C Chapuy, and C Bressot, and E Vignon, and M Arlot, and L Mathieu, and C Edouard, and C C Johnston, and P J Meunier
November 1975, Revue du rhumatisme et des maladies osteo-articulaires,
C Alexandre, and M C Chapuy, and C Bressot, and E Vignon, and M Arlot, and L Mathieu, and C Edouard, and C C Johnston, and P J Meunier
January 1981, Metabolic bone disease & related research,
Copied contents to your clipboard!